31.10.2023 - FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder . Seite 1
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 29, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Aldeyra.
MALVERN, Pa., Sept. 18, 2023 Galera Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that.
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Galera Receives Complete Response Letter from U S FDA for Avasopasem Manganese itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.